Paper

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

Published Dec 20, 2021 · Jingwen Ai, Jitao Wang, Dengxiang Liu

Clinical Gastroenterology and Hepatology

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCTLarge Human Trial

Study Snapshot

Inactivated whole-virion SARS-CoV-2 vaccines are safe for patients with chronic liver diseases, but have lower immunologic response compared to healthy individuals.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

References

Citations